To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Sanofi Website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

respiratory-syncytial-virus

Respiratory syncytial virus

Nirsevimab&nbsp;is a long-acting human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infections in infants and young children.
Key Features:
Single-dose protection&nbsp;- Provides protection throughout the entire RSV season with just one injection
Broad population coverage&nbsp;- Designed for ALL infants:
<ul>
 <li>Healthy term and late preterm infants</li>
 <li>Preterm infants</li>
 <li>Infants with chronic lung disease (CLD) or congenital heart disease (CHD)</li>
</ul>
Administration &amp; Dosing:&nbsp;
<ul>
 <li>Route: Intramuscular injection</li>
 <li>Dosing: 
 <ul>
 <li>50 mg&nbsp;for infants weighing&nbsp;&lt; 5 kg</li>
 <li>100 mg&nbsp;for infants weighing&nbsp;≥ 5 kg</li>
 </ul></li>
 <li>Timing: Administered before or at the start of RSV season, regardless of birth timing</li>
</ul>
Frequently Asked Questions (FAQs):
RSV Immunization: Target Patient Population

Who is recommended to receive RSV immunization?

If the infant is healthy, does RSV pose a significant risk?

Can Nirsevimab be given to preterm infants?

Duration of protection:

How long does the RSV protection by nirsevimab last?

Administration:

The infant is very young; can't we wait until they're older to address RSV prevention?

Is there a minimum interval between palivizumab and Nirsevimab, if an infant has received at least 1 dose (but less than 5 doses) of palivizumab?&nbsp;

Can I administer two 50 mg doses of nirsevimab to my patient who is &gt; 5 kg instead of a 100 mg dose?

Can we split a 100 mg manufacturer-filled syringe (MFS) of nirsevimab into two 50 mg doses?

Can RSV immunization be co-administered with other routine vaccines?

Can an infant or young child receive RSV immunization when they are sick?

Should I administer RSV immunization to an infant who is born at the very end of the RSV season?

If a high-risk child mistakenly received a 100 mg dose of Nirsevimab when they should have received a 200 mg dose, should we have them return for the other 100mg?

Will infants born during the RSV season receive RSV immunization before they are discharged from the hospital?

If a patient was born towards the end of season and did not receive RSV immunization, can they receive RSV immunization in beginning of next season?

Should an infant who had a confirmed RSV infection this season still receive RSV immunization?

Because nirsevimab is a monoclonal antibody product, who can administer it?

Safety Profile:

Is Nirsevimab safe? Will the infant be in pain or get a fever?

Are there any contraindications to receiving RSV immunization?

Supply:

Should we anticipate limitations in nirsevimab supply for the RSV season?

References

Nirsevimab FAQs

RESPIRATORY-SYNCYTIAL-VIRUS

VACCINES

Saudi National immunization strategy for RSV prevention

WEQAYA General Guidelines for Introducing the Long-Acting Antibody for (RSV) - AR

WEQAYA General Guidelines for Introducing the Long-Acting Antibody for (RSV) - EN

Ensuring overall RSV prevention in every individual Dr. Alia Podcast

This video explains WEQAYA's strategy on Nirsevimab Implementation

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

Nirsevimab is given for infants entering their first RSV season as a single injection based on infant's weight at the time of dosing
<h2>How to use Nirsevimab</h2>

Nirsevimab comes in a ready-to-use pre-filled syringes with no need to reconstitute&nbsp;
Given as an intramuscular injection, preferably into the anterolateral aspect of the thigh&nbsp;
Can be administered concomitantly with childhood vaccines
<h2>How to store Nirsevimab</h2>

<h2>When to administer Nirsevimab&nbsp;</h2>
The duration of protection afforded by Nirsevimab is at least 5 months.

Illustrative example only. For full dosing information, consult the Summary of Product Characteristics.
<h2>Luer Lock Syringe Components</h2>

Step 1: Holding the Luer lock in one hand, unscrew the syringe cap by twisting it counter-clockwise with the other hand.

Step 2: Attach a Luer lock needle to the pre-flled syringe by gently twisting the needle clockwise onto the pre-filled syringe until slight resistance is felt.&nbsp; (16mm-25mm)

Step 3: Hold the syringe body with one hand and carefully pull the needle cover straight off with the other hand.

Step 4: Administer the entire contents of the Nirsevimab pre-filled syringe as an IM injection, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used as an injection site because of the risk of damage to the sciatic nerve.

Step 5: Discard syringe into a sharps container.

SANOFI, Kingdom of Saudi Arabia, PO Box 9874, Jeddah 21423, K.S.A. Tel.: +966-12-669-3318 
 For further medical information, please contact: 
 KSA / +966-12-669-3318 or email:&nbsp;<a href="mailto:ksa.medicalinformation@sanofi.com">ksa.medicalinformation@sanofi.com</a>&nbsp; 
 To report adverse events please contact: The National Pharmacovigilance Center (NPC):&nbsp;Call Center: 19999, E-mail: <a href="mailto:npc.drug@sfda.gov.sa">npc.drug@sfda.gov.sa</a>, Website:&nbsp;<a href="https://ade.sfda.gov.sa/">https://ade.sfda.gov.sa/</a>&nbsp;And&nbsp;Sanofi Pharmacovigilance Department: Phone: +966-544-284-797, E-mail:&nbsp;<a href="mailto:Ksa_pharmacovigilance@sanofi.com">Ksa_pharmacovigilance@sanofi.com</a>&nbsp; 
 To report any product technical complaints, kindly contact: email:&nbsp;<a href="mailto:quality.greatergulf@sanofi.com">quality.greatergulf@sanofi.com</a> Sanofi Gulf, One JLT, 3rd floor, JLT. PO BOX - 53899, Dubai - UAE For further medical information, please contact: For UAE ✆ 800 MEDICAL Toll-Free Number. For all Gulf countries ✆ +97145503863 or email: medical-information.gulf@sanofi.com. To report an adverse event or drug reaction, please contact us on 24/7 Pharmacovigilance:+971561747001 | Email: gulf.pharmacovigilance@sanofi.com. To report any product technical complaints, kindly contact: quality.greatergulf@sanofi.com

Respiratory syncytial virus

Latest Articles

Nirsevimab FAQs

Saudi National immunization strategy for RSV prevention

Ensuring overall RSV prevention in every individual Dr. Alia Podcast

Latest Resources

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

An easy guide to use Nirsevimab